{"entity":{"id":"lucence","kind":"company","name":"Lucence","aka":[],"tldr":"Lucence offers blood tests that read both tumour DNA and tumour RNA from a single sample to help doctors choose targeted treatments, and is developing a multi-cancer screening test.","summary":"Lucence is a precision diagnostics company with laboratories in Singapore and Palo Alto, California, and an office in Hong Kong. Its AmpliMARK amplicon-based technology enables ultrasensitive detection of cell-free DNA and RNA. The flagship LiquidHALLMARK assay profiles circulating tumour DNA and RNA in one blood draw to identify actionable mutations and fusions in solid tumours, with a cerebrospinal fluid version for central nervous system cancers. LucenceINSIGHT is a multi-cancer early detection (MCED) test the company states screens at 99 percent specificity, and LucenceMONITOR addresses treatment monitoring. Laboratories are CAP-accredited and CLIA-certified. Data on combined ctDNA and ctRNA yield were presented at ASCO 2025, and in March 2026 Lucence, DxD Hub and the National Cancer Centre Singapore launched an S$6 million research collaboration.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lucence.com/"},{"label":"News and updates","url":"https://www.lucence.com/news-updates"},{"label":"About Lucence","url":"https://www.lucence.com/about"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","breast-hr-positive"],"sections":["diagnostics","early-detection"],"technologies":["liquid-biopsy","cgp","rna-seq","mced"],"targets":["egfr","alk","kras","ret","ntrk","met"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round could be sourced from primary releases on the company site; stage set to startup provisionally. Founding year not sourced. Cancer and target tags reflect typical LiquidHALLMARK coverage described generically on the site rather than a fetched panel list."],"hq":"Singapore","country":"SG","companyType":"diagnostics","website":"https://www.lucence.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/lucence/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}]}}